Received: 12 November 2020
Accepted: 16 March 2021
First Online: 6 April 2021
: The <i>Swiss HCVree Trial</i> was approved by the lead ethic committee in Zurich, Switzerland (ExternalRef removed) under the reference number BASEC 2016–00131 (locally responsible for the University Hospital Zurich and Klinik im Park). Local ethics committee Bern (University Hospital Bern), Northwest/Central (EKNZ) (University Hospital Basel), Geneva (University Hospital of Geneva), Ostschweiz (EKOS) (Cantonal Hospital St. Gallen), Ticino (Regional Hospital Lugano), and Vaud (University Hospital Center Lausanne) approved as well. The study was carried out in accordance with principles enunciated in the current version of the Declaration of Helsinki, the guidelines of Good Clinical Practice (GCP) issued by ICH, and Swiss competent authority’s requirements.All participants provided written informed consent prior to participation.
: Not Applicable.
: PKH received consultancy fees from Eisai, and grants from ViiV, Merck, and Janssen; all outside the submitted work.KF has no conflict of interest.AJS has no conflict of interest.MR has no conflict of interest.JB has no conflict of interest.AK reports grant from Merck outside submitted work.SE has no conflict of interest.MB has no conflict of interest.CN has no conflict of interest.AL has no conflict of interest.RK has no conflict of interest.PS received travel grants from Merck, outside submitted work.DLB received consultancy fees from Merck, Gilead, and ViiV.JF is a member of the Federal Commission for Sexual Health. He received research, educational and travel grants from Janssen, Merck and ViiV Healthcare.DN reports grants from Merck, Janssen, and ViiV outside submitted work.